DW-1350 is a LTB4 receptor antagonist.
DW-1350 is a LTB4 receptor antagonist. DW-1350 shows inhibitory effects against osteoclast in terms of differentiation, formation, fusion and bone absorption[1].
[1]. Kang JH, et al. 5-Lipoxygenase inhibitors suppress RANKL-induced osteoclast formation via NFATc1expression. Bioorg Med Chem. 2015 Nov 1;23(21):7069-78.
















